These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 2169783

  • 1. A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. The Granisetron Study Group.
    Marty M.
    Eur J Cancer; 1990; 26 Suppl 1():S28-32. PubMed ID: 2169783
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group.
    Chevallier B.
    Eur J Cancer; 1990; 26 Suppl 1():S33-6. PubMed ID: 2169784
    [Abstract] [Full Text] [Related]

  • 3. The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis.
    Cupissol DR, Serrou B, Caubel M.
    Eur J Cancer; 1990; 26 Suppl 1():S23-7. PubMed ID: 2169782
    [Abstract] [Full Text] [Related]

  • 4. A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. The Granisetron Study Group.
    Smith IE.
    Eur J Cancer; 1990; 26 Suppl 1():S19-23. PubMed ID: 2169780
    [Abstract] [Full Text] [Related]

  • 5. An overview on the use of granisetron in the treatment of emesis associated with cytostatic chemotherapy.
    Tabona MV.
    Eur J Cancer; 1990; 26 Suppl 1():S37-44. PubMed ID: 2169785
    [Abstract] [Full Text] [Related]

  • 6. A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group.
    Soukop M.
    Eur J Cancer; 1990; 26 Suppl 1():S15-9. PubMed ID: 2169779
    [Abstract] [Full Text] [Related]

  • 7. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
    Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F, Aprepitant Protocol 054 Study Group.
    Cancer; 2003 Jun 15; 97(12):3090-8. PubMed ID: 12784346
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG.
    Semin Oncol; 1994 Oct 15; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ, Tzeng WF, Wang WS, Yen CC, Fan FS, Liu JH, Chen PM.
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct 15; 63(10):729-36. PubMed ID: 11076429
    [Abstract] [Full Text] [Related]

  • 11. The symptomatic control of cytostatic drug-induced emesis. A recent history and review.
    Joss RA, Brand BC, Buser KS, Cerny T.
    Eur J Cancer; 1990 Oct 15; 26 Suppl 1():S2-8. PubMed ID: 2169781
    [Abstract] [Full Text] [Related]

  • 12. Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation.
    Spitzer TR, Friedman CJ, Bushnell W, Frankel SR, Raschko J.
    Bone Marrow Transplant; 2000 Jul 15; 26(2):203-10. PubMed ID: 10918432
    [Abstract] [Full Text] [Related]

  • 13. Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma.
    Numbenjapon T, Sriswasdi C, Mongkonsritragoon W, Leelasiri A, Prayoonwiwat W.
    J Med Assoc Thai; 2002 Nov 15; 85(11):1156-63. PubMed ID: 12546311
    [Abstract] [Full Text] [Related]

  • 14. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R, Herrstedt J, Rapoport B, Carides AD, Guoguang-Ma J, Elmer M, Schmidt C, Evans JK, Horgan KJ.
    Eur J Cancer; 2004 Feb 15; 40(3):403-10. PubMed ID: 14746859
    [Abstract] [Full Text] [Related]

  • 15. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ.
    Cancer; 2003 May 01; 97(9):2290-300. PubMed ID: 12712486
    [Abstract] [Full Text] [Related]

  • 16. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
    Perez EA.
    Cancer J Sci Am; 1998 May 01; 4(2):72-7. PubMed ID: 9532406
    [Abstract] [Full Text] [Related]

  • 17. [A comparative study of the effects of granisetron alone and a combination of granisetron plus steroids on CDDP-based combination chemotherapy-induced emesis--outcomes of a multicenter randomized comparative study using the central registration method. Nara Medical University Kytril Study Group].
    Ozono S, Okajima E, Hirao YK, Natsume O, Kaneko Y, Ohara S, Tabata S, Watanabe S, Aoyama H, Sasaki K, Matsuki H, Takashima K, Maruyama Y, Yoshikawa M, Yamada K, Momose H, Hiramatsu T, Hayashi Y, Babaya K, Shiomi T.
    Gan To Kagaku Ryoho; 1997 Feb 01; 24(3):349-56. PubMed ID: 9051139
    [Abstract] [Full Text] [Related]

  • 18. Granisetron in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study.
    Okamoto S, Takahashi S, Tanosaki R, Sakamaki H, Onozawa Y, Oh H, Miyawaki S, Kimura Y, Toyama K, Ikeda Y, Asano S.
    Bone Marrow Transplant; 1996 May 01; 17(5):679-83. PubMed ID: 8733681
    [Abstract] [Full Text] [Related]

  • 19. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy.
    Ettinger DS, Eisenberg PD, Fitts D, Friedman C, Wilson-Lynch K, Yocom K.
    Cancer; 1996 Jul 01; 78(1):144-51. PubMed ID: 8646710
    [Abstract] [Full Text] [Related]

  • 20. Granisetron in the prevention of irradiation-induced emesis.
    Prentice HG, Cunningham S, Gandhi L, Cunningham J, Collis C, Hamon MD.
    Bone Marrow Transplant; 1995 Mar 01; 15(3):445-8. PubMed ID: 7599570
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.